We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




开发的分子血检法检测肾癌

By LabMedica International staff writers
Posted on 17 Oct 2017
Print article
图片:TaqMan低密度阵列卡示例;每孔含一个特定miRNA正向引物,一个特定的miRNA TaqMan探针,一个反向引物“尾巴”(照片由Dana-Farber Cancer Institute提供)。
图片:TaqMan低密度阵列卡示例;每孔含一个特定miRNA正向引物,一个特定的miRNA TaqMan探针,一个反向引物“尾巴”(照片由Dana-Farber Cancer Institute提供)。
肾癌通常容易发现,因为肾癌患者的症状明显,但在肿瘤长到很大产生疼痛或其他值得注意的问题前,肾癌也可能没有症状。
涉及肾细胞癌(RCC)发生和发展的机制仍不明确,且常规实践需要新的生物标志物,以改善其诊断和/或预后的准确性。正在开发肾癌的血检法能改善这种疾病的筛查,并有助于确保在患者无症状而仍能治疗时被诊断出来。
金陵医院(中国,南京)的一个科学家团队检测33名患者和33名健康志愿者血样中754种不同microRNA(miRNA)的浓度,这些患者有最常见类型的肾癌(肾细胞癌)。对754种miRNA的初始微阵列调查使用TaqMan低密度阵列,随后使用基于水解探针的定量逆转录聚合酶链式反应(RT-qPCR)验证血清样本,鉴别RCC中显著失调的miRNA。还检验了17对肿瘤组织中miR-651和miR-708的表达水平。此外,体外检验包括CCK8扩增、Transwell实验和划痕实验,开展这些试验以探索RCC中miR-651和miR-708的潜在功能。荧光素酶报告实验联合蛋白质印迹法,用于验证靶基因。
该团队发现,检验验证了RCC患者与非癌对照者相比,4种miRNA的血清水平显著升高,但4种miRNA的水平显著降低。统计分析揭示,这8种microRNA中,肾癌患者中两种已知的miR-651和miR-708降低,曲线下面积最大(分别为0.888和0.832)。这就意味着,这些microRNA的检测能以相对高的准确度诊断肾细胞癌。他们还研究了miR-651和miR-708的功能,并发现表明他们作为肿瘤抑制物的证据。一种增高miR-651和miR-708水平的治疗因此可能是肾细胞癌的一种新疗法。
该研究的第一作者Chunni Zhang博士说,“尚不明确肾细胞癌发生和发展的机制,没有标准的血清生物标志物方便诊断这种疾病患者。miR-651和miR-708都可能作为肾细胞癌的新生物标志物,并可能作为肿瘤抑制物。我们的研究显示,一种以miR-651和miR-708为目标的基因法可能提供一种治疗肾细胞癌的新策略。”本研究在第69届美国临床化学协会(AACC)年会暨临床实验室博览会上展示,该展会于7月30日至8月3日在美国加州的圣地亚哥召开。

Related Links:
金陵医院 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: A false color scanning election micrograph of lung cancer cells grown in culture (Photo courtesy of Anne Weston)

AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell

Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.